CD19 and multiple sclerosis: When comparing the effects of two monoclonal antibodies, anti-CD19 and anti-CD20, on an animal model of multiple sclerosis, anti-CD19 is more effective than anti-CD20 in reducing autoantibodies and plasma cells that cause inflammation and damage in the nervous system.